Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
Recent posts
Lexington, MA-based Pulmatrix, which is developing inhalable therapies for a variety of lung disorders, said today it is promoting chief scientific officer Robert Clarke to CEO. He will be replacing former... Read more »
Xconomy is gearing up for what’s sure to be a stimulating panel event, Xconomy Xchange: Reinventing Biotech’s Business Model for the Big Apple, which will be held the evening of Thursday,... Read more »
Boston-based OvaScience, which is developing infertility treatments based on stem cell science, filed documents with the SEC announcing its plans to go public. According to the filing, the company intends to... Read more »
Jonathan Lewis, the CEO of New York-based Ziopharm (NASDAQ: ZIOP), was stunned earlier this year when he ran across a commercial on YouTube produced by his company’s biggest investor, Fidelity.... Read more »
Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has formed a 10-year strategic alliance with St. Louis-based agricultural giant Monsanto (NYSE: MON) to develop biotech solutions for the farming industry.... Read more »
After Jay Parkinson completed his residency at Johns Hopkins and started practicing medicine in Williamsburg, Brooklyn, in 2007, he set out to make doctor-patient communications as seamless as possible. His patients... Read more »
Whitehouse Station, NJ-based pharmaceutical giant Merck (NYSE: MRK) provided an update Sunday on three of its experimental drugs to treat cardiovascular conditions during the European Society of Cardiology meeting in Munich.
In... Read more »
The pharmaceutical world went into shock on August 6, when Pfizer, Johnson & Johnson, and Elan Pharmaceuticals pulled the plug on bapineuzumab (“bapi”), a highly anticipated experimental drug they were co-developing to... Read more »
On August 16, New York-based TG Therapeutics (OTCBB: TGTX) announced that it had formed a deal with a Swiss company called Rhizen Pharmaceuticals to co-develop a drug to treat blood... Read more »
Anybody with diabetes who searches their iPhone for an app to help them monitor their blood sugar will likely be overwhelmed by the choices. A simple search using the word “glucose”... Read more »
Boston-based Best Doctors, which was founded by Harvard physicians in 1989, has brought in $45.5 million in new funding, according to an SEC filing. Brown Brothers Harriman & Co. provided... Read more »
Ever since Jennifer Johnson started working in financial services in the 1990s, she felt something was missing in all the technology available to traders who want to get information about stocks.... Read more »
When Marc Beer joined Cambridge, MA-based Aegerion Pharmaceuticals (NASDAQ:AEGR) as CEO in August 2010, the company was $4 million in debt, nearly insolvent, and “not following a clear path,”... Read more »
The Alzheimer’s drug being jointly developed by New York area drug giants Pfizer and Johnson & Johnson, along with Ireland’s Elan Pharmaceuticals, was so fondly anticipated on Wall Street over the... Read more »
When Anderson Gaweco started his biotech company in New York in 2010, he planned to follow the standard entrepreneurship blueprint-for-success and pursue venture capital financing. But the more Gaweco learned about... Read more »
Enlight Biosciences, a pharma industry-backed entrepreneurial venture, unveiled its newest portfolio company today, Knode. The Cambridge, MA-based startup, which is developing a LinkedIn-like social networking tool for drug companies, has formed... Read more »
In the annals of cancer medicine, radiation has a long and distinguished reputation as a potent weapon. But like all cancer treatments, radiation can cause side effects, because it attacks healthy... Read more »
New York City has everything to offer to anyone interested in working in biotech, from top-notch science programs at colleges like Columbia and NYU, to access to top venture capitalists. So... Read more »
Cambridge, MA-based Mersana Therapeutics announced today it has raised $27 million in a Series A-1 financing. The company brought in new investors Pfizer Venture Investments and New Enterprise Associates (NEA). Existing... Read more »
Ever since Genentech’s clot dissolver known as tissue plasminogen activator, or tPA, hit the market 15 years ago, the pharmaceutical industry has been laboring to come up with something to solve... Read more »
